While still not from BOT so therefore take it with a grain of salt, this is from the E&P report - Page 41
In the U.S., seven major plans cover approximately 80% of lives, making these engagements crucial. While the progress of thesenegotiations remains somewhat opaque and reliant on optimistic company guidance, it is assumed that Sofdra will be reimbursed at alevel commensurate with a unit list price of approximately $750 per prescription, with a gross-to-net adjustment of around 30%.
While still not from BOT so therefore take it with a grain of...
-
- There are more pages in this discussion • 200 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.025(7.46%) |
Mkt cap ! $567.0M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.5¢ | 33.3¢ | $14.94M | 42.66M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 112268 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 276101 | 7 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |